Clinical trial · no report yet · Phase not applicable

OligoRARE trial: what clinicians have said so far

Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)

NCT04498767 ↗
Recruiting
European Organisation for Research and Treatment of Cancer - EORTC
Deep size, estimated: 301+ verified statements

We haven't built an HCP commentary report on OligoRARE (rare oligometastatic cancers; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on OligoRARE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
46 posts on X
2 YouTube videos
1 podcast episode

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial
Phase: Phase not applicable
Status: Recruiting
Conditions: Gynecologic Cancer; Skin Cancer; Head and Neck Cancer; Sarcoma; Renal Cancer; Bladder Cancer; Upper Urinary Tract Carcinoma; Pancreatic Cancer; Hepatobiliary Cancer; Gastric Cancer; Small Bowel Cancer; Esophageal Cancer; Melanoma; Colon Cancer; Oligometastasis
Interventions: Stereotactic body radiotherapy; Palliative RT
Arms: Arm 1: Standard of Care + palliative RT · Active comparator
Arm 2: Standard of Care + SBRT · Experimental
Enrollment: 200 (estimated)
Primary outcomes: Overall survival
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC with Anticancer Fund, Belgium, Rising Tide Foundation
Start: Jun 10, 2021
Primary completion: Aug 1, 2028 (estimated)
Results posted: No
Registry record: NCT04498767 · updated Aug 26, 2024

Get this report

Deep

Report, built on orderBuilt within 24 hours of confirming your order: $1,950

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md

Indexed commentary on OligoRARE so far

Reports on the same drug or indication

The trial